New pill shows promise in early breast cancer trial
NCT ID NCT05654532
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental oral drug called AC699 in 100 adults with a common type of advanced breast cancer (ER+/HER2-). The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tumors. Participants must have already tried standard treatments without success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AC699 (an oral drug)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced ER+/HER2- breast cancer who have run out of standard options.
What could go wrong
This is a very early (Phase 1) trial, so the main goal is safety, not effectiveness. The drug may not shrink tumors or could cause side effects. Only 100 people are enrolled, so results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 01
Nashville, Tennessee, 37203, United States
-
Site 02
Sarasota, Florida, 34232, United States
-
Site 03
Houston, Texas, 77030, United States
-
Site 04
Vancouver, Washington, 98684, United States
-
Site 05
Norfolk, Virginia, 23502, United States
-
Site 06
Rockville, Maryland, 21044, United States
-
Site 07
Orlando, Florida, 32746, United States
-
Site 08
Denver, Colorado, 80218, United States
-
Site 09
San Antonio, Texas, 78240, United States